RecruitingPhase 1Phase 2NCT06097832

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Phase 1b/2 Study of NXC-201 for the Treatment of Patients With Relapsed or Refractory AL Amyloidosis

Sponsor

Nexcella Inc.

Enrollment

40 participants

Start Date

Jun 5, 2024

Study Type

INTERVENTIONAL

Conditions

Light Chain (AL) Amyloidosis

Summary

Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).

Eligibility

Min Age: 18 YearsMax Age: 120 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called NXC-201 CAR-T for people with light chain (al) amyloidosis. The study is currently recruiting participants at 18 locations. People eligible for this study include aged 18 Years to 120 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALNXC-201 CAR-T

NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryopreservation.

Locations(18)

Sutter Health Alta Bates

Berkeley, California, United States

City of Hope

Duarte, California, United States

University of California Los Angeles

Los Angeles, California, United States

University of California Davis Medical Center

Sacramento, California, United States

Stanford University

Stanford, California, United States

Winship Cancer Institute, Emory University

Atlanta, Georgia, United States

The University of Kansas Cancer Center

Fairway, Kansas, United States

Tufts Medical Center

Boston, Massachusetts, United States

Boston University Medical Center

Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, United States

Washington University Siteman Cancer Center

St Louis, Missouri, United States

Memorial Sloan Kettering Comprehensive Cancer Center

New York, New York, United States

University of Cincinnati Cancer Center

Cincinnati, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

Baptist Memorial Hospital

Memphis, Tennessee, United States

Huntsman Cancer Institute at the University of Utah

Salt Lake City, Utah, United States

Swedish Cancer Institute

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06097832

Related Trials

Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

NCT066298181 location

Daratumumab for Patients With Light Chain Amyloidosis

NCT063762141 location